Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes

Sana Biotechnology (NASDAQ:SANA) is one of the small cap stocks with the highest upside potential. On April 13, Sana Biotechnology and Mayo Clinic entered into a collaboration to accelerate the development of SC451, an investigational cell replacement therapy for type 1 diabetes. SC451 uses Sana Biotech’s proprietary hypoimmune technology to engineer pancreatic islet cells that can survive and function without the need for traditional immunosuppression or daily insulin injections.

As part of this partnership, Mayo Clinic has made an equity investment in Sana Biotech, reflecting a shared goal of creating potentially curative therapies that can be standardized and scaled for global use. The collaboration focuses on using Mayo Clinic’s multidisciplinary expertise to refine the clinical and operational protocols necessary for delivering SC451. Efforts will include optimizing product handling, refining surgical procedural techniques, and improving post-treatment care to ensure the therapy can be adopted across various clinical environments.

Nestor Rizhniak/Shutterstock.com

Additionally, Mayo Clinic will provide leadership in clinical trial design and biomarker identification to enhance patient selection and long-term monitoring as the therapy moves toward human trials. Sana Biotechnology (NASDAQ:SANA) aims to initiate a Phase 1 clinical study for SC451 as early as this year, bolstered by recent data showing that hypoimmune-modified islets survived and produced insulin in a patient for over 14 months without immunosuppression.

Sana Biotechnology (NASDAQ:SANA) is a biotech company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.